Plant Name: Haplopappus venetus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; HTR7; HTR5A; ADRA1A; ADRA2C; ADRB2; ADRB3; ADRA1D; ADRA2A; ADRA2B; DRD2; HTR4; HTR1F; HTR1B; HTR1D; HTR1E; DRD3; HTR2B; HTR2A; HTR1A; HTR2C; HTR6; | |
| OPRK1; OPRD1; OPRM1; | |
| GABBR1; | |
| TDP1; BLM; MPO; HSD17B10; | |
| HTR3A; | |
| GABRR1; | |
| MAPK1; | |
| KDM4E; | |
| HIF1A; | |
| KMT2A; | |
| ABCB1; | |
| SLC6A1; SLC6A11; SLC6A4; | |
| LMNA; NPC1; RAB9A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| 5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | OPRM1 | Mu opioid receptor | P35372 | CHEMBL233 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| SLC superfamily of solute carriers | SLC6A4 | Serotonin transporter | P31645 | CHEMBL228 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRB2 | Beta-2 adrenergic receptor | P07550 | CHEMBL210 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | ADRA1D | Alpha-1d adrenergic receptor | P25100 | CHEMBL223 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR4 | Serotonin 4 (5-HT4) receptor | Q13639 | CHEMBL1875 |
| Small molecule receptor (family A GPCR) | HTR1F | Serotonin 1f (5-HT1f) receptor | P30939 | CHEMBL1805 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | HTR1E | Serotonin 1e (5-HT1e) receptor | P28566 | CHEMBL2182 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.409E-12 | 1.237E-09 | ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 2.814E-11 | 9.146E-09 | HTR1A, HTR1B, HTR5A, HTR7 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 5.775E-09 | 1.245E-06 | DRD2, DRD3, HTR1B, HTR2A, OPRK1 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 7.781E-09 | 1.629E-06 | ADRA2C, DRD2, DRD3, GABBR1, HIF1A, HTR2A, HTR2B, HTR3A, HTR5A, HTR6, MAPK1, OPRD1, OPRK1, OPRM1, SLC6A1, SLC6A11, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 9.174E-09 | 1.885E-06 | DRD2, DRD3, HTR1B, HTR2B |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 1.175E-08 | 2.284E-06 | ADRA2A, DRD2, DRD3, GABBR1, OPRM1 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.264E-08 | 2.436E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 5.047E-08 | 8.326E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 5.047E-08 | 8.326E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.260E-07 | 1.905E-05 | HTR2A, HTR2B, HTR2C |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 1.260E-07 | 1.905E-05 | ADRA2A, ADRB2, ADRB3 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.326E-07 | 1.991E-05 | DRD2, DRD3, HTR2A, OPRK1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.356E-07 | 2.023E-05 | ADRA2A, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTR2C, MAPK1, NPC1, OPRK1 |
| BP | GO:0009987; cellular process | GO:0014062; regulation of serotonin secretion | 4.394E-07 | 5.730E-05 | HTR1A, HTR1B, SLC6A4 |
| BP | GO:0007610; behavior | GO:0042755; eating behavior | 5.526E-07 | 7.120E-05 | ADRB3, OPRD1, OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 7.019E-07 | 8.491E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0004985; opioid receptor activity | 7.019E-07 | 8.491E-05 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 9.639E-07 | 1.110E-04 | DRD2, DRD3, OPRK1, OPRM1 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.095E-06 | 1.223E-04 | ADRA1A, ADRA1D, ADRA2C, HTR2A |
| BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 1.239E-06 | 1.369E-04 | ADRA2C, OPRD1, OPRK1, OPRM1 |
| CC | GO:0016020; membrane | GO:0098590; plasma membrane region | 2.157E-06 | 2.302E-04 | ABCB1, ADRA1A, ADRA2A, ADRB2, DRD2, GABBR1, GABRR1, HTR2A, HTR3A, MAPK1, OPRD1, OPRM1 |
| CC | GO:0044464; cell part | GO:0030424; axon | 2.338E-06 | 2.472E-04 | ADRA2C, DRD2, HTR2A, HTR3A, MAPK1, OPRM1, SLC6A1 |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 3.904E-06 | 3.918E-04 | DRD2, HTR2A, HTR2B, HTR2C |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 4.517E-06 | 4.495E-04 | DRD2, HTR1B, HTR2A |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 5.072E-06 | 5.020E-04 | DRD2, DRD3, HIF1A, KMT2A |
| BP | GO:0009987; cellular process | GO:0031635; adenylate cyclase-inhibiting opioid receptor signaling pathway | 5.548E-06 | 5.346E-04 | OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 5.548E-06 | 5.346E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 5.548E-06 | 5.346E-04 | HTR2A, HTR2C |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 5.547E-06 | 5.346E-04 | ADRA1A, HTR2A, MAPK1, NPC1, OPRD1, OPRM1, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.956E-06 | 6.445E-04 | ADRA1A, DRD2, HTR2A, HTR2B, HTR2C, OPRM1 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 7.731E-06 | 7.013E-04 | DRD2, HTR5A, MAPK1, OPRK1, OPRM1 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 8.783E-06 | 7.838E-04 | ADRA2C, DRD2, OPRD1, OPRK1 |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 1.006E-05 | 8.865E-04 | ADRA2A, ADRA2C, ADRB3 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 3.824E-30 | 1.665E-26 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.838E-26 | 3.639E-23 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.838E-26 | 3.639E-23 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 7.256E-25 | 1.317E-21 | ADORA3, ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, DRD2, DRD3, GABBR1, GABRR1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, NPC1, OPRD1, OPRK1, OPRM1, SLC6A1, SLC6A11, SLC6A4 |
| MF | GO:0005488; binding | GO:0001965; G-protein alpha-subunit binding | 1.192E-05 | 1.022E-03 | HTR2A, HTR2B, OPRM1 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 1.662E-05 | 1.381E-03 | DRD2, DRD3 |
| MF | GO:0060089; molecular transducer activity | GO:0004937; alpha1-adrenergic receptor activity | 1.662E-05 | 1.381E-03 | ADRA1A, ADRA1D |
| MF | GO:0005488; binding | GO:0042923; neuropeptide binding | 1.886E-05 | 1.544E-03 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 2.080E-05 | 1.659E-03 | ADRA2A, DRD2, DRD3, HTR1B, HTR2A |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 2.302E-05 | 1.803E-03 | ADRA2A, DRD2, HTR2A, HTR2B, HTR2C |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 2.470E-05 | 1.907E-03 | ADRA1A, HTR2A, HTR2B |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 3.163E-05 | 2.399E-03 | CYP1A2, CYP2A6, CYP2D6 |
| BP | GO:0065007; biological regulation | GO:0001994; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure | 3.319E-05 | 2.475E-03 | ADRA1A, ADRA1D |
| BP | GO:0032501; multicellular organismal process | GO:0014827; intestine smooth muscle contraction | 3.319E-05 | 2.475E-03 | HTR1D, HTR2B |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 3.319E-05 | 2.475E-03 | SLC6A1, SLC6A11 |
| BP | GO:0050896; response to stimulus | GO:2001025; positive regulation of response to drug | 3.552E-05 | 2.622E-03 | DRD2, KMT2A, OPRK1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.580E-05 | 2.633E-03 | ADRA1D, ADRA2A, DRD2, DRD3, HIF1A, HTR1A, HTR1B, HTR2A, HTR2B, MAPK1 |
| BP | GO:0051179; localization | GO:0051590; positive regulation of neurotransmitter transport | 4.422E-05 | 3.147E-03 | DRD2, SLC6A1, SLC6A4 |
| BP | GO:0050896; response to stimulus | GO:0071502; cellular response to temperature stimulus | 5.523E-05 | 3.794E-03 | HTR1B, HTR2B |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 5.523E-05 | 3.794E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 5.797E-05 | 3.938E-03 | BLM, DRD2, DRD3, HIF1A, KMT2A, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0071312; cellular response to alkaloid | 6.559E-05 | 4.381E-03 | BLM, HTR1B, OPRM1 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 7.182E-05 | 4.739E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0032501; multicellular organismal process | GO:0045987; positive regulation of smooth muscle contraction | 7.182E-05 | 4.739E-03 | ADRA1A, ADRA1D, ADRA2B |
| BP | GO:0023052; signaling | GO:0032229; negative regulation of synaptic transmission, GABAergic | 8.272E-05 | 5.377E-03 | HTR1B, SLC6A1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.272E-05 | 5.377E-03 | CYP1A2, CYP2D6 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 8.633E-05 | 5.562E-03 | ADRA2A, DRD2, HTR2A, OPRK1 |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 9.279E-05 | 5.891E-03 | ADORA3, ADRB2, ADRB3 |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.094E-04 | 6.846E-03 | ADRA2A, ADRB2, ADRB3, GABBR1, GABRR1, HTR3A |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.156E-04 | 7.093E-03 | CYP1A2, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:1903715; regulation of aerobic respiration | 1.156E-04 | 7.093E-03 | HIF1A, OPRK1 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.156E-04 | 7.093E-03 | CYP2A6, CYP2D6 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.321E-04 | 8.057E-03 | DRD2, DRD3, HTR2A, HTR2B, HTR2C |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.351E-04 | 8.219E-03 | ADRA2A, ADRA2B, ADRA2C, MAPK1 |
| BP | GO:0051179; localization | GO:0015812; gamma-aminobutyric acid transport | 1.539E-04 | 9.109E-03 | SLC6A1, SLC6A11 |
| BP | GO:0032501; multicellular organismal process | GO:0031649; heat generation | 1.539E-04 | 9.109E-03 | ADRB2, ADRB3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 1.539E-04 | 9.109E-03 | DRD2, DRD3 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 1.539E-04 | 9.109E-03 | DRD2, DRD3 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.870E-22 | 4.013E-19 | ADORA3, ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, DRD2, DRD3, GABBR1, GABRR1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, NPC1, OPRD1, OPRK1, OPRM1 |
| MF | Unclassified; | GO:0004872; receptor activity | 6.597E-21 | 5.131E-18 | ADORA3, ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, DRD2, DRD3, GABBR1, GABRR1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, NPC1, OPRD1, OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 6.706E-17 | 3.562E-14 | ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, DRD2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.974E-39 | 7.408E-37 | OPRD1; HTR2B; HTR2C; ADRA1D; ADRB2; HTR2A; HTR4; ADRA1A; HTR6; GABRR1; HTR7; ADORA3; DRD2; DRD3; GABBR1; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; OPRK1; OPRM1; HTR5A; ADRA2C; ADRA2B; ADRA2A; ADRB3 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.645E-25 | 1.640E-23 | HTR1E; HTR1F; HTR1D; HTR1A; HTR2B; HTR1B; HTR2C; HTR3A; HTR2A; HTR5A; HTR4; SLC6A4; HTR6; HTR7; CYP2D6; MAPK1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.341E-13 | 9.677E-12 | HTR6; HTR7; ADRB3; HTR2B; HTR2C; ADRA1D; ADRB2; HTR2A; HTR5A; HTR4; ADRA1A |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.057E-13 | 2.188E-11 | HTR6; GABBR1; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; MAPK1; ADRB2; HTR4; DRD2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.952E-12 | 9.801E-11 | OPRD1; ADRB3; ADORA3; MAPK1; ADRA1D; ADRB2; ADRA2C; ADRA2B; ADRA1A; ADRA2A |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 7.692E-10 | 1.590E-08 | GABBR1; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; HTR3A |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.748E-06 | 3.097E-05 | HTR2B; HTR2C; MAPK1; HTR2A; DRD2 |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 4.958E-05 | 6.427E-04 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa04970 | Salivary secretion_Homo sapiens_hsa04970 | 5.183E-05 | 6.427E-04 | ADRB3; ADRA1D; ADRB2; ADRA1A |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.690E-04 | 4.160E-03 | MAPK1; ADRA1D; ADRB2; ADRA1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.364E-04 | 5.543E-03 | CYP2A6; CYP2D6; CYP1A2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.327E-04 | 6.035E-03 | CYP2A6; CYP2D6; CYP1A2 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.486E-03 | 1.186E-02 | HTR2B; HTR2C; HTR2A |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 1.201E-03 | 1.063E-02 | GABBR1; GABRR1; OPRM1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.530E-03 | 1.186E-02 | GABBR1; MAPK1; OPRM1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.650E-03 | 1.825E-02 | MAPK1; ADRA1D; ADRA1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.650E-03 | 1.825E-02 | OPRD1; ADORA3; MAPK1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.365E-03 | 4.807E-02 | ADRB3; ADRB2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.153E-05 | 6.427E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Bradycardia | NA | ADRB2 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | ADRB3; ADRB3; ADRB3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HTR3A; HTR3A; DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Narcotic depression | F19.20, F32 | OPRM1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; ADRA1D |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; ADRA1D |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A |
| NA: NA | Primary insomnia | NA | HTR2C |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; ADRA2C; ADRB2; ADRB3; ADRA1D; DRD2; DRD2; HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Aging skin | L00-L99 | ADRB2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3; HTR1D; HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; ADRB3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR1A; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD2; HTR1A; HTR1B; DRD3; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; OPRM1; DRD2; SLC6A4 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRK1; ADRA2C; ADRB2; ADRB3; ADRB3; ADRB3; OPRM1; HTR2C; HTR2C; SLC6A4; HTR6 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; OPRM1; DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | ADRB2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Analgesia | R52, G89 | OPRM1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR3A; ADRB3; HTR2B |
| NA: NA | Itching | NA | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1; HTR6 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; HTR2C; HTR6 |
| N00-N99: Diseases of the genitourinary system | Neurogenic bladder dysfunction | N31.9 | ADRB2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; DRD2; HTR1A; HTR1B; HTR2A; HTR2C; HTR6; HTR6 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3; DRD2 |
| NA: NA | Anxiety disorders | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; SLC6A4; SLC6A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | OPRM1 |
| NA: NA | Heart block | NA | ADRB2 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Mild pain | R52, G89 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | OPRM1; HTR1D; HTR1A; HTR1F; HTR2B; HTR2A; CYP2D6; SLC6A4 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; HTR1D; HTR1B; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD2; DRD2; DRD2; DRD2; HTR1A; HTR1A; DRD3; HTR2A; HTR2A; HTR2C; SLC6A4; HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; HTR7; ADRA1A; ADRB3; ADRB3; OPRM1; DRD2; HTR1D; HTR1A; HTR1A; HTR1B; HTR2C; HTR2C; SLC6A4; SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depression | F32, F33 | SLC6A4 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | ADRA1D |
| NA: NA | Episode | NA | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D |
| L00-L99: Diseases of the skin and subcutaneous tissue | Skin infections | L00-L99 | ADRB2 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; ADRA2C; ADRB3; ADRA1D; DRD2; ADORA3; HTR2A |
| NA: NA | Addiction | NA | HTR2A |
| NA: NA | Menopausal staging | NA | SLC6A4 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Smoking cessation | F17.2 | SLC6A4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Pediatric cancer | C00-C96 | ADRA1D |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| NA: NA | Exacerbations of acute asthma | NA | ADRB2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; MAPK1 |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | General anesthesia | R20.0 | OPRM1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; OPRM1; OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Movement disorder | R25 | OPRM1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; HIF1A; MAPK1; ADORA3; SLC6A4 |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; HTR1A; DRD3 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRK1; OPRD1; ADRA2C; ADRA2B; DRD2; HTR2A; HTR2C |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1; DRD2; DRD2; DRD2; DRD2 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | ADRA1D |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRB3; ADRA1D; HTR2A; HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; ADRB2; HTR1A; SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1D; HTR1A; HTR1B; HTR2A; HTR2C; SLC6A4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe acute pain | R52, G89 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A; HTR2C |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; ADRB2 |
| NA: NA | Myalgia | NA | SLC6A4 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ADRB2 |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | ADRB2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; HTR1A; HTR2B; HTR2A; HTR2C; SLC6A4; SLC6A4; SLC6A4 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1; OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | OPRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C |
| J00-J99: Diseases of the respiratory system | Acute asthma | J45 | ADRB2 |
| NA: NA | Chemotherapyinduced emesis | NA | SLC6A4 |
| J00-J99: Diseases of the respiratory system | Chronic breathing disorders | J44-J47 | ADRB2 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| NA: NA | Appetite suppressant | NA | SLC6A4 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | OPRK1; DRD2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; ADORA3 |
| NA: NA | Cervical dystonia | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Systemic pain | R52, G89 | OPRM1 |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; HTR1A; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| NA: NA | Hyperaemia | NA | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; DRD2; HTR1A; HTR1A; HTR6; HTR6; HTR6 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | OPRM1; SLC6A4 |
| NA: NA | Chronic low back pain | NA | SLC6A4 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ADRB2; ADRB2; ADRB2; ADRB3; DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR3A; DRD2; DRD3; HTR6 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| NA: NA | Corneal vascularity | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; ADRB2; ADRB2; ADRB2; ADRB3; ADRB3; OPRM1; DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fecal incontinence | R15 | ADRA1D |
| NA: NA | False perceptions | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | ADRA1D; HTR2B |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | OPRM1 |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; ADRA1A; ADRA1D |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR3A; ADRA2C; HTR2A; SLC6A4; SLC6A4 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| NA: NA | Social phobia | NA | HTR1A |
| K00-K95: Diseases of the digestive system | Opioid-induced constipation | K59.0 | OPRM1 |
| NA: NA | Vomiting | NA | HTR3A; DRD2 |
| NA: NA | Depressive disorders | NA | SLC6A4 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1; OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| N00-N99: Diseases of the genitourinary system | Vasomotor symptoms | N95.1 | SLC6A4 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRK1; OPRD1; ADRA1A; ADRA2C; ADRA2A; OPRM1; OPRM1; DRD2; HTR1A; HTR2C; SLC6A4 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; DRD2; HTR1A; SLC6A4 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; ADRA1A; ADRB3; ADRA1D; OPRM1; HTR1A |